Healthcare
Live Price
Offline$6.95
+0.72% today
1Y Change
+49.78%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xeris Biopharma Holdings, Inc. (XERS) is a Healthcare stock with a market cap of $1.09B and listed on NASDAQ. The stock last traded around $6.95 and up 49.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +43.7%, EPS growth of +100.9%, a dividend yield of 0.0%. What stands out right now is revenue +43.7%, EPS +100.9%, free cash flow +173.8% with operating margin 8.5% and ROIC 8.9%. Valuation already assumes a fairly strong business story at P/E 1899.3 and price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XERS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XERS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XERS Max Drawdown
-46.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XERS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$49.6M
-55.0% YoY
FY Net Income
-$122.7M
-29.6% YoY
Free Cash Flow
-$103.4M
+0.0% YoY
Revenue Growth
+43.7%
EPS Growth
+100.9%
Gross Margin
81.7%
Net Margin
0.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 292M | 203M | 164M | 110M | 50M |
| Gross Profit | 238M | 166M | 135M | 88M | 36M |
| Operating Income | 25M | -34M | -44M | -82M | -115M |
| EBITDA | 13M | -14M | -24M | -69M | -114M |
| Net Income | 554K | -55M | -62M | -95M | -123M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 111M | 72M | 67M | 122M | 67M |
| Total Assets | 384M | 323M | 323M | 345M | 304M |
| Total Liabilities | 370M | 353M | 329M | 299M | 209M |
| Shareholder Equity | 14M | -30M | -7M | 45M | 95M |
| Total Debt | 38M | 271M | 229M | 198M | 88M |
| Net Debt | -73M | 200M | 162M | 76M | 21M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
103M
+0.0% YoY
Capital Expenditures
524K
+0.0% YoY
Free Cash Flow
103M
+0.0% YoY
Key ratios
Gross Margin
81.7%
Operating Margin
8.5%
Net Margin
0.2%
ROE
-5.3%
Debt / Equity
2.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.